See What HealthDay Can Do For You
Contact Us

High Costs for False-Positive Mammograms, Overdiagnosis

National expenditure estimated at $4 billion/year for false-positive mammograms, breast CA overdiagnosis

THURSDAY, April 9, 2015 (HealthDay News) -- Mammography screening is associated with considerable costs linked to false-positive mammograms and breast cancer overdiagnosis, with national expenditure estimated at $4 billion annually, according to a study published in the April issue of Health Affairs.

Mei-Sing Ong, Ph.D., from Boston Children's Hospital, and Kenneth D. Mandl, M.D., M.P.H., from Harvard Medical School in Boston, examined the costs due to false-positive mammograms and breast cancer overdiagnosis among women aged 40 to 59 years. Expenditure data were extracted from a major U.S. health care insurance plan for 702,154 women in the years 2011 to 2013.

The researchers found that in the 12 months following diagnosis, the average expenditures were $852, $51,837, and $12,369, respectively, for each false-positive mammogram, invasive breast cancer, and ductal carcinoma in situ. The national cost was estimated at $4 billion per year.

"The costs associated with false-positive mammograms and breast cancer overdiagnoses appear to be much higher than previously documented," the authors write. "Screening has the potential to save lives. However, the economic impact of false-positive mammography results and breast cancer overdiagnoses must be considered in the debate about the appropriate populations for screening."

Full Text (subscription or payment may be required)

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.